/
AERI
$15.25+$0.01 (+0.07%)prev close
Change+$2.31
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
P/S (TTM)
3.4
EV / FCF (TTM)
384
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc. operates as a pharmaceutical enterprise focused on the discovery, development, and commercialization of ophthalmic treatments for the U.S. market. The company's therapeutic scope includes open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration. Its commercialized portfolio features Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure (IOP) for patients with open-angle glaucoma or ocular hypertension. Also available is Rocklatan, a daily fixed-dose combination of Rhopressa and latanoprost, which similarly works to reduce IOP in individuals with these conditions. In its development pipeline, Aerie is advancing AR-15512 to address the symptoms and signs of dry eye, alongside AR-1105 and AR-14034 SR, which are sustained-release implants targeting various retinal diseases. The company also engages in a collaborative research, development, and licensing agreement with DSM Biomedical. Established in 2005, Aerie Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
www.alcon.com/alcon-completes-acquisition-aerie- Employees
- 376
- IPO / List date
- Oct 25, 2013
- HQ
- US
Held by traders on TradeandTell
No one on the platform currently holds AERI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AERI as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AERI yet.
